Dianthus Therapeutics (DNTH) Earnings Date, Estimates & Call Transcripts → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free DNTH Stock Alerts $21.50 +0.51 (+2.43%) (As of 04/26/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateJun. 20EstimatedActual EPS (Mar. 21) -$0.71 Beat By $0.40 Consensus EPS (Mar. 21) -$1.11 Get Dianthus Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for DNTH and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueDNTH Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.DNTH Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. Dianthus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.79)($0.79)($0.79)Q2 20241($0.84)($0.84)($0.84)Q3 20241($0.88)($0.88)($0.88)Q4 20241($0.94)($0.94)($0.94)FY 20244($3.45)($3.45)($3.45)DNTH Earnings Date and InformationDianthus Therapeutics last announced its quarterly earnings data on March 21st, 2024. The reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.40. The company earned $0.46 million during the quarter, compared to analyst estimates of $0.73 million. Dianthus Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($1.92) to ($2.12) per share. Dianthus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 20th, 2024 based off prior year's report dates.Read More Dianthus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 6/20/2024Estimated)------- 3/21/2024Q4 2023($1.11)($0.71)+$0.40($0.71)$0.73 million$0.46 million11/9/2023Q3 2023($0.51)($3.78)($3.27)($3.78)$0.50 million$0.92 million8/3/2023Q2 2023($3.04)($0.80)+$2.24($0.80)--11/3/2022Q3 2022($4.96)($4.32)+$0.64($4.32)--8/4/2022Q2 2022($5.92)($4.64)+$1.28($4.64)--5/16/2022Q1 2022($5.44)($6.24)($0.80)($6.24)-- Get the Latest News and Ratings for DNTH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/8/2022Q4 2021($5.12)($5.28)($0.16)($5.28)--11/4/2021Q3 2021($5.12)($4.80)+$0.32($4.80)--8/5/2021Q2 2021($5.60)($5.12)+$0.48($5.12)--5/6/2021Q1 2021($6.40)($5.76)+$0.64($5.76)-- Dianthus Therapeutics Earnings - Frequently Asked Questions When is Dianthus Therapeutics's earnings date? Dianthus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, June 20th, 2024 based off last year's report dates. Learn more on DNTH's earnings history. Did Dianthus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Dianthus Therapeutics (NASDAQ:DNTH) reported ($0.71) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.11) by $0.40. Learn more on analysts' earnings estimate vs. DNTH's actual earnings. How much revenue does Dianthus Therapeutics generate each year? Dianthus Therapeutics (NASDAQ:DNTH) has a recorded annual revenue of $2.83 million. How much profit does Dianthus Therapeutics generate each year? Dianthus Therapeutics (NASDAQ:DNTH) has a recorded net income of -$43.56 million. DNTH has generated $0.00 earnings per share over the last four quarters. What is Dianthus Therapeutics's EPS forecast for next year? Dianthus Therapeutics's earnings are expected to decrease from ($1.92) per share to ($2.12) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Bicycle Therapeutics Earnings Date Nurix Therapeutics Earnings Date Evolus Earnings Date Silence Therapeutics Earnings Date Y-mAbs Therapeutics Earnings Date Cogent Biosciences Earnings Date Disc Medicine Earnings Date Pharming Group Earnings Date Savara Earnings Date Aerovate Therapeutics Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:DNTH) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
